PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-62.27%
R&D reduction while AXSM shows 10.62% growth. Joel Greenblatt would examine competitive risk.
43.14%
G&A change of 43.14% while AXSM maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.75%
Operating expenses reduction while AXSM shows 6.62% growth. Joel Greenblatt would examine advantage.
-7.75%
Total costs reduction while AXSM shows 8.31% growth. Joel Greenblatt would examine advantage.
-100.00%
Interest expense reduction while AXSM shows 24.56% growth. Joel Greenblatt would examine advantage.
975.86%
D&A growth while AXSM reduces D&A. John Neff would investigate differences.
-265.35%
EBITDA decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
7.75%
Operating income growth below 50% of AXSM's 35.57%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-2437.42%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-313.81%
Pre-tax income decline while AXSM shows 17.64% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine advantage.
-313.81%
Net income decline while AXSM shows 19.26% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-286.19%
EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
-286.19%
Diluted EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
6.89%
Share count reduction below 50% of AXSM's 1.17%. Michael Burry would check for concerns.
6.89%
Diluted share reduction below 50% of AXSM's 1.17%. Michael Burry would check for concerns.